S7 mia, hypoaldosteronism, and priapism. These side effects are relatively rare in a given individual, but given the extremely widespread use of heparin, some are quite common, particularly HITT and osteoporosis. Although reasonable incidences of many of these side effects can be "softly" deduced from current reports dealing with unfractionated heparin. at present the incidences of these side effects with newer low molecular weight heparins appear to be much less common. However, only longer experience will more clearly define the incidence of each side effect with low molecular weight preparations. Key Words: Heparin-Heparin side effects-HITT-Osteoporosis-Alopecia-Bleeding-Thrombosis. recogruuon of the related therapeutic concepts have largely evolved only during the past decade (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) .
Two clinical forms of HIT are now recognized, The first, commonly termed HIT type I is a nonidiosyncratic, nonimmunologic form ( Table 2 ). The thrombocytopenia occurs early in the exposure, within the first few days of therapy in the heparin naive and within hours in the patient previously exposed to heparin. The decline in platelet numbers is modest (10% to 30%), and is not associated with any clinical manifestations. The decline in platelet numbers is the result of platelet aggregation by mechanism(s) that are uncertain; nevertheless, the aggregation is associated with platelet sequestration and increased consumption. High(er) molecular weight heparins have the greatest likelihood of producing this change. Of particular interest is that the episodes are transient and platelet counts normalize by unknown mechanisms, despite continued exposure to heparin, There is no evidence that this clinical-laboratory event is related to the more serious immune form of HIT (commonly termed HIT type II).
By contrast, HIT type II is an immune-mediated lesion with serious clinical sequelae and significant morbidity and mortality (7, 9, 13, 15, 17) . HIT type II will be discussed in the following and will be referred to as HIT, as has become the common practice. Some have considered this lesion to have two subtypes, HIT and HITT, the latter serving to recognize the presence of thrombosis, Episode of thrombocytopenia occurs early in exposure: Generally in first few days in naive and in first hours in previously exposed Mild thrombocytopenia: 1O-30')f, decrease in platelet numbers Clinical manifestations: None Mechanism: Heparin-induced platelet aggregation True incidence: Uncertain; but common Biologic issues: Episode transient; counts normalize even with continued heparin Therapy: None Relationship 10 HIT type II: Unclear, but probably none which is often the important clinical result of immune heparin-induced thrombocytopenia. Table 3 lists the common clinical characteristics of this lesion. Although the usual recognition of the decreased number of platelets is generally after several days of therapy (3-14 days), with the median day being day 10, prior exposure to heparin can result in precipitous declines in circulating platelet numbers within hours. In addition. most instances of HITT involve antibodies to the multimolecular heparin/platelet factor 4 complex (lgG. IgA. or IgM idiotypes); however, rarer antibodies appear to be against platelet membrane interleukin 8 (lL-8) or platelet membrane neutrophil-activating peptide-2 (NAP-2) receptors. These rarer forms may not behave typically with respect to temporal relationships with heparin delivery or degree of decrease in platelet count.
Historically, the parameter of diagnostic recognition was a decrease in platelets to below 100-150 x IO'J/L. It is now clear that clinical sequelae can occur when a significant decline in the platelet number occurs. even when the usual parameter of true thrombocytopenia is not present (17) . Therefore. there is no specific platelet number that one should usc to trigger suspicion of the presence of HIT. The best working rule is that the diagnosis must be suspected if the platelet count falls by 30% from the baseline and should be strongly considered or ruled out when the platelet count has declined to 50% of baseline levels (17, 18) . This infers that the thrombocytopenia may be relative rather than absolute, because the patients' baseline values may not be in the 250-400 x (17) . An appropriate postoperative clinical parameter is that for any patient whose platelet count declines 20% to 30% from a day I postoperative value. the physician should suspect HIT and follow such individuals with daily platelet counts. When HIT is suspected in any medical or surgical patient it is important to plot the platelet count on a graph, noting the rate of decline and temporal relationships to heparin administration. Typically. the rate of decline. as with other immune-mediated thrombocytopenias, is rapid (even more rapid than other immune thrombocytopenias) and typically more rapid than nonimmune causes of thrombocytopenia (DIC. marrow suppressive mechanisms. including medications, sepsis. and other causes).
An important clinical rule is that HIT can occur with any amount or type of heparin, administered by any route. Although it is most common with continuous infusion of unfractionated heparin, it has occurred with heparin flushes as low as 500Ulday and even with heparin-coated catheters where the delivery can be as low as 3U1hour (19.20) .
An important component of HIT is the development of thrombotic lesions. This is ominous and is associated with significant morbidity and mortality. Its threat. thera-
S9 peutic urgency, and treatment complexities are such that the term heparin-induced thrombocytopenia-thrombosis (often abbreviated HITI) has been applied to highlight this sequence, and considerable effort has been expended to attempt to define risk factors for its occurrence (21, 22) . It is of interest that even with very severe thrombocytopenia (counts < 10 x 109/L) thrombosis is a more common sequelae than bleeding. It should be noted that in the earlier literature regarding HIT, the event of vascular thrombosis was almost entirely correlated with large vessel arterial occlusions. Indeed the term "white clot syndrome" had been used to highlight the event of a massive, arterial occlusion of the lower extremity (21, 23, 24) . Clinical experience has now identified thrombotic sequelae in arterial and venous circulation (19, 24, 25) . Unfortunately, in a given patient who has developed HIT, the clinician cannot predict the subsequent advent of thrombosis. It is, however, evident that in patients who develop HIT in juxtaposition to recent surgery, the thrombosis occurs most commonly in the venous circulation. In contrast, the occurrence of HIT in patients with preexisting cardiovascular disease commonly results in arterial occlusions (19, 22, 26) . In addition, pulmonary emboli (PE) are common in medical and surgical patients developing HITI. Attempts to better characterize the risks have indicated that the incidence of HIT is similar in men and women, and age is not a factor. Therefore, when strongly suspecting HIT not only must the heparin be immediately withdrawn, but a careful search for evidence of thrombosis must be initiated. Also, the presence of inherited deficiencies of clotting factors (i.e., antithrombin, protein C or protein S) or other mutations (i.e, factor V Leiden, prothrombin G2021OA) do not correlate with the occurrence of HIT or the thrombotic sequelae (i.e., HITI).
The diagnostic criteria for HIT are shown in Table 4 . Although past definitions have included a definable platelet number to denote the degree of thrombocytopenia, these parameters no longer strictly apply as dis-Cussed previously. Classically one would expect that another cause of the thrombocytopenia has been excluded. Unfortunately, the temporal events in HIT are often so abrupt that a long agonizing clinical evaluation of other potential mechanisms to explain the thrombocytopenia often can contribute to severe clinical sequelae (17, 18) . Therefore, this criteria is interpreted to mean that clinical 
. Heparin-induced thrombocytopenia-type II (immune-idiosyncratic)
Common diagnostic criteria I. Thrombocytopenia: Decrease of 50% or more from baseline platelet number 2. Absence of other cause 3. Confirmation by a heparin-associated antibody assay 4. Return to normal platelet numbers when heparin is stopped judgment has eliminated other causes (including noting the rate of platelet count decrease, temporal relationships with heparin, and evaluation of comorbid conditions and medications) and that HIT is the most likely responsible diagnosis. In a similar manner, a delay in diagnosis and therapy to await a serologic confirmation is, in general, no longer acceptable. From the studies of Walenga et al. the multiplicity of tests and lack of an absolute "gold standard" further emphasizes the importance of clinical judgment (17, 18 ). An important basis for such a conclusion is related to some of the complex temporal relationships in the clinical features of HIT. Thus, as many as 45% of the thrombotic episodes of HIT occur in the first 48 hours after identification of the thrombocytopenia. A delay in diagnosis to await laboratory confirmation can, therefore, result in serious clinical risk to the patient. In addition, it must not be assumed that other comorbid conditions or medications are automatically responsible for the thrombocytopenia.
A second issue relates to comorbid diseases. Concurrent illness can alter the pattern and severity of onset of HIT. An even more difficult aspect of HIT is the circumstance of "delayed onset of HIT". Clinical features and thrombocytopenia have developed 7 to 14 days after discontinuing heparin therapy, and thrombosis has been described up to I month after heparin discontinuation (15) . Although uncommon, the clinician must be aware of this potential, and this further complicates the role of confirmatory testing. A related caveat is of clinical concern. The comorbid condition of the patient can have a significant effect on this pattern of development and similarly can affect the expected temporal pattern of repair of circulating platelet numbers after cessation of heparin.
Several clinical laboratory features are characteristic. Thus, although thrombocytopenia is the cardinal laboratory feature, bleeding is uncommon. Thrombosis, by contrast, is the clinical event that primarily results in morbidity and mortality in HIT. The classical descriptions defined the "white clot syndrome" with an associated abrupt occlusion of a major artery. Although this does represent a dramatic event of acutely emergent care requirement, it is now clear that thrombi in small arterial and arteriolar beds as well as venous occlusive lesions are more common. The latter are estimated to occur with 3-fold frequency over arterial lesions (7, 9, 12, 13, (16) (17) (18) 21, 23) . PE are also common. Important clinical clues to the potential occurrence of HIT include the recognition of "relative" heparin resistance during induction of heparin therapy or the presence of unexplained chills, fever, and constitutional symptoms. Four other rare clinical events can occur as part of the evolution of HIT and should alert the physician to the development of the syndrome: (A) skin necrosis, (B) transient global amnesia, (C) thrombosis on a present prosthetic valve, or (0) bleeding into the adrenal glands with the abrupt development of adrenal insufficiency.
The true incidence of HIT is not certain, although an occurrence in 3% to 5% of all heparin-treated individuals is a reasonable estimate. The diagnostic parameters are not absolute. In the past significant or severe thrombocytopenia was the initial and frequently the only identifying marker. The recent clinical observations have more clearly defined a 50% decrease from baseline platelet levels (17, 18) . It has been common to demand a "confirmatory" laboratory test. As has been well-defined, no single laboratory test recognizes all clinical cases of HIT, and many medical centers lack the ability to perform such assays (17, 18) . Therefore, if the incidence data required absolute confirmatory testing, the number of cases identified would be greatly reduced. In addition, the absolute incidence is affected by comorbid conditions, so that patients who present with a thrombosis for heparin therapy or who are given heparin for thrombosis prophylaxis during an orthopedic surgical procedure have a higher incidence than general hospital populations (27) (28) (29) (30) (31) . Incidence figures also relate to the mode of heparin therapy, as it is well established that continuous infusion is more commonly associated with HIT than intermittent unfractionated heparin; and each are more common than therapy with low molecular weight heparins.
The delineation of the incidence of the most important clinical sequelae of HIT, that of thrombosis is more difficult. Estimates of such a thrombosis in a patient with HIT are as high as 35%, and in those patients who develop such a thrombosis, amputation rates of 25% and mortality of 25% to 30% have been reported (7,9,14,15. 17,18,25) . The incidence of HITT appears to be about 1% (1/ I00 patients) of patients receiving unfractionated heparin for at least 5 days (32, 33) . All such data must be considered tentative until firm diagnostic criteria are more widely accepted and prospective studies are done where the comorbid conditions are well-documented. Although our current incidence data may be "soft," it is clear that morbidity and mortality in HIT are significant; and therefore, the clinical recognition of the syndrome and proper therapy are critical. Finally, it merits note that data from a variety of centers has suggested that the occurrence of HIT predicts future significant thrombotic events, further emphasizing the importance of clinical awareness.
There are several existent controversies in the emerging clinical understanding of HIT. First, the level of platelet numbers or change of platelet numbers from the baseline level to serve as the clinical parameter of diagnosis and thereby provide the parameter to perform other laboratory studies and alter therapy is not absolutely established. Second, the issue of whether incidence can only be defined by a specific serologic assay continues to be controversial and will probably always be so as long CIi" Apl'l Thrmnbosis/Hemostasis, Vol. 5, SlIl'pl. I. 191.J1J as no single absolute assay defines all cases. We believe that the clinical evidence that up to 45% of thrombotic episodes occur in the first 48 hours of the recognition of HIT strongly interdicts "waiting for laboratory confirmation" prior to therapeutic action, particularly when excellent alternatives to heparin are available. Third, the exact incidence of thrombosis is not well defined in HIT, but is thought to be I% of those receiving unfractionated heparin for 5 days. Fourth, whether the clinical sense that an HIT thrombosis is clinically more dangerous in circumstances in which the patient is being treated with heparin for a present thrombosis. and the true role of comorbid conditions are not settled issues. Fifth, the relationship of an uncommonly described event, that of the paradoxical thrombotic complication of venous limb gangrene in patients on heparin during their transition to oral anticoagulant therapy with warfarin, is not fully clarified. However, many of these patients are now known to harbor an acquired protein C deficiency that may accentuate or precipitate this problem (34) .
Prevention of HITT is dependent on careful observation of platelet counts. For inpatients receiving intravenous or subcutaneous heparin/low molecular weight heparin therapy we recommend a baseline platelet count followed by a platelet count every other day for the first 14 days of therapy. After day 14, a repeat platelet count is immediately indicated if there are indications or evidence of new thrombi during heparin therapy or the subsequent 2 weeks of posthospital care. For outpatient heparin/low molecular weight heparin therapy, a baseline platelet count is needed and then repeated on day 3 and day 5 (at which point antithrornbotic therapy is usually transitioned solely to warfarin, which is started on day I, simultaneous with initiation of heparin).
TREATMENT OF HIT/HITT
Several immediate measures must be undertaken as soon as a clinical diagnosis of HIT/HIIT is made. The first imperative measure is to immediately stop heparin; like any immune-mediated adverse reaction, the "antigen" (heparin) must be promptly removed. Next, the clinician must make a decision regarding the need for rapid institution of alteroative antithrombotic therapy. In many patients, the underlying thrombosis or hypercoagulable condition for which the patient was initially placed on heparin will still be present; in this case rapid institution of alternate antithrombotic therapy is necessary. In addition, when making a diagnosis of HIT, the clinician must immediately suspect the possibility of thrombosis/ thromboembolism (HIIT) and institute a diligent search for thrombosis with color flow Doppler of the lower extremity deep veins, ventilation/perfusion scan (V/P lung scan), MRA (MRI with contrast studies) of the abdominal vasculature, and other diagnostic tests for thrombosis. If this search is positive for clinical or occult thrombosis, rapid institution of antithrombotic therapy is also indicated. The only agent currently FDA approved for this purpose is recombinant hirudin (lepirudin). Other agents for rapid institution of antithrombotic therapy in HIT/HITT, argatroban, hirulog, danaparoid, and ancrod are pending FDA approval. If no thrombosis is present and the clinical condition for which the patient was initially heparinized has abated, rapid (35) or routine warfarinization may be considered. However. before embarking on this rapid warfarinization approach (35) it is mandatory that functional protein C and protein S levels are measured. Similarly, such testing is also desirable in patients receiving routine warfarinization. For those patients needing rapid warfarinization, a protocol for quick warfarinization, within 24 hours. recently has been published (35) . If the patient only requires prophylactic therapy with heparin and has a prior or current history of HIT/HITT, then lepirudin (10 to 20 mg subcutaneously every 12 hours) has been advocated (36) . Table 5 provides a practical summary of treatment for HIT/HITT.
BLEEDING
The most common and more regularly anticipated complication of heparin therapy is bleeding (31, (37) (38) (39) (40) (41) (42) . The true incidence of major bleeding has been sought, but currently there is only an estimate of 6% to 14% (39, 40) . Hirsh and colleagues have emphasized important variables relative to heparin-related bleeding (19,39. 40) . These are (a) the dose of heparin administered, (b) the method of administration (i.e.. continuous vs. intermittent. etc.), and (c) the comorbid and concomitant therapy administered. Heparin therapy is more commonly associated with bleeding when given to chronic alcoholics (37) . More complex and not completely resolved is the consideration that bleeding is more commonly seen in patients on aspirin (37, 40, 42) . Because this is a not uncommon treatment combination in patients with arterial vascular disease, clinical vigilance for bleeding is the only intelligent approach.
ACUTE HEPARIN REACTION (? ANAPHYLAXIS)
A rare, but potentially lethal acute reaction to heparin can occur. The event is abrupt and clinically dramatic (43) . It has occurred only in patients previously treated with heparin. It again merits emphasis that the heparin exposure need not be a quantitative exposure, because it has occurred with heparin exposure as minimal as heparin flush or with the use of a heparin-coated catheter. Symptoms occur dramatically within 5 to 10 minutes of institution of the heparin bolus and include abrupt onset of chills and fever. tachycardia, diaphoresis. and nausea. Hypotension may be noted, although most patients have become abruptly and transiently hypertensive. Retrosternal chest pain with the pattern of an acute myocardial infarction is common. Finally, a global amnesia syndrome has been linked to the crisis event. This anaphylaxislike reaction has all of the features of an immunoglobulin E-stimulated response. Immediate cessation of heparin is critical. Other nonheparin antithrombotic agents should be used to treat patient.
HEPARIN-ASSOCIATED OSTEOPOROSIS
Prolonged heparin exposure has been correlated with the development of osteoporosis (44, 45) . The clinical findings that led to the evaluation of this finding were the unexpected development of bone pain or the identification of vertebral body or rib fractures. The clinical correlate was that the patient had been on long-term heparin (> 6 months) and usually at daily doses> 15,000 anti-Xu units (19) . Limited epidemiologic and controlled studies are available to define the incidence of heparinassociated osteoporosis. In addition, many of the studies have focused on pregnant patients because such patients represent a group likely to have a long duration of therapy. However, since pregnancy itself is commonly associated with osteoporosis, such data must be cautiously interpreted. Howell et al, in randomized trials identified a 5% incidence of vertebral fractures in women treated during their pregnancy with unfractionated heparin (46) . Monreal et al. (42) in a randomized study of 40 men and 40 women (mean age of 68) on long-term heparin therapy identified a 10% incidence of vertebral fractures (47) . Six of seven fractures occurred with unfractionated heparin, the seventh with low molecular weight heparin (Fragrnin). An interesting finding in this study was that there was no difference in bone density between the group developing fractures and those without fractures. There was no correlation between lumbar bone density and dose or duration of therapy (47) .
Barbour and associates evaluated the subclinical occurrence of heparin-associated osteoporosis in pregnancy by means of bone densitometry in a prospective, consecutive cohort of 14 pregnant women requiring heparin therapy and 14 pregnant controls matched for age, race and smoking status (48). Proximal femur bone density measurements were taken at baseline, immediately postpartum, and 6 months postpartum in the cases and controls. Vertebral measurements were also obtained on both groups immediately postpartum and 6 months postpartum. Bone density relative to heparin dose and duration was examined. Five of 14 cases (36%) had a 10% decrease from their baseline proximal femur measurements to their immediate postpartum values, whereas none occurred in the 14 matched controls (p = 0.04).
Mean proximal femur bone density measurements also decreased and this difference was still statistically significant 6 months postpartum (p = 0.03). This study concluded that no clear dose-response relationship could be demonstrated, and that unfractionated heparin adversely affected bone density in about 33% of exposed patients (48).
Dahlman studied the effect of long-term heparin treatment during pregnancy and the incidence of osteoporotic fractures and thromboembolic recurrence (49) . Longterm subcutaneous prophylaxis with heparin twice daily in pregnancy was used in 184 individuals. The dose of heparin was adjusted to anti-factor Xa activity or activated partial thromboplastin time. Different regimens were given depending on risk stratification. Symptomatic osteoporotic fractures of the spine occurred postpartum in four women (2.2%). Their mean dosage of heparin ranged from 15,000 to 30,000 IV per 24 hours (mean 24,500 IU per 24 hours), and duration of treatment was from 7 to 27 weeks (mean 17 weeks). It is of interest that in spite of prophylaxis with heparin, thromboembolic complications occurred in five women. Thus, osteoporotic vertebral fractures were found in 2.2%, and these did correlate with the amount of heparin administered. There were no thrombocytopenias or excessive hemorrhage. Hunt et aI., during a study of low molecular weight heparin (Fragrnin) for thromboprophylaxis in 34 high-risk pregnancies identified one woman who developed an osteoporotic vertebral collapse postpartum (50) . This woman had no other risk factors for osteoporosis. Parenthetically, this study did support the efficacy of low molecular weight heparin in preventing recurrent thromboembolic disease in pregnant women at high risk. In this study, the incidence of osteoporotic fracture was 3%; however, bone density studies, to assess asymptomatic osteoporosis were not reported.
In a prospective matched cohort, Douketis et al. studied the effects of long-term (> I month) unfractionated heparin therapy on lumbar spine bone density (51) . Twenty-five women who received heparin during prcg-nancy, and 25 matched controls underwent dual photon absorptiometry of the lumbar spine in the postpartum period. None of the 25 heparin-treated patients developed fractures. Heparin-treated patients had a 0.082 g/crrr' lower bone density compared to untreated controls, which was statistically significant (p = 0.0077).
There were six matched pairs in which only the heparintreated patient had a bone density below 1.0 g/cnr', compared to only one pair in which only the control patient had a bone density below this level (p = 0.089). The duration of heparin therapy, the mean daily dose, and the total dose of heparin were not at levels of independent significance. They concluded that long-term heparin therapy was associated with a significant reduction in bone density, although fractures are uncommon. They could not show a correlation between the lumber bone density and the dose or duration of heparin therapy. This is in contradistinction to the generally held views that heparin-induced osteoporosis is related to the dose and duration of therapy (17, 18) .
A variety of studies have focused on the mechanism whereby heparin affects bone metabolism and structure. Muir et al. treated rats with once daily subcutaneous injections of unfractionated heparin or saline for 8 to 32 days and monitored the effects on bone histomorphometrically and measured urinary type I collagen crosslinked pyridinoline (PYD) and serum alkaline phosphatase as surrogate markers of bone resorption and formation (52) . Biochemical markers of bone turnover showed that heparin produced a dose-dependent decrease in serum alkaline phosphatase and a transient increase in urinary PYD, thus confirming the histornorphornetric data. They concluded that heparin decreases trabecular bone volume by decreasing the rate of bone formation and increasing the rate of bone resorption (52) . In a subsequent study, this group evaluated the effect of low molecular weight heparin in a similar model system (53) . It was found that both unfractionated and low molecular weight heparin decreased cancellous bone volume in a dose-dependent fashion, but heparin caused significantly more bone loss than the low molecular weight heparin. The biochemical markers of bone turnover demonstrated that both heparins produced a dose-dependent decrease in serum alkaline phosphatase, which was consistent with reduced bone formation whereas, only the unfractionated heparin caused an increase in urinary PYD, which was consistent with increased bone resorption. They concluded that unfractionated heparin decreases cancellous bone volume by decreasing the rate of bone formation and increasing the rate of bone resorption. In contrast low molecular weight heparin causes less osteopenia because it only decreases the rate of bone formation (53 (54) . Shaughnessy, et al. further examined the issue of calcium loss by an in vitro calcium release assay and demonstrated that size and sulfation of the heparins were the major determinants of the promotion of bone resorption (55) . Their extrapolation was that low molecular weight heparin preparations would, therefore, reduce the risk of the expected heparin-associated osteoporosis.
Murray and associates examined bone density in a rabbit model (56) . A reduction in cortical and trabecular bone density was seen with unfractionated heparin (p < 0.05) and high molecular weight heparin (p < 0.0 I), but not with low molecular weight heparin.
Thus, heparin-associated osteoporosis is a clinically uncommon event occurring in less than 5% of long-term heparin-treated patients. The evidence supports a lesser risk with low molecular weight heparin than with unfractionated heparin. The mechanisms appear related to impaired bone deposition and formation plus enhanced bone resorption with unfractionated heparin. A change in new bone deposition appears to be the major mechanism with low molecular weight heparin. Most clinical evidence supports the view that a long duration of therapy (Le., > 6 months) and a higher dose of heparin increases the risk of bone changes.
From these observations, we currently recommend that bone density studies be done at 6 months in patients Whose duration of therapy will be > 6 months at an eqUivalent of 20,000 anti-Xa U/day or at 3 months if the dose will exceed 20,000 anti-X Ulday. In addition, we encourage calcium supplements. If the patient is going to be on low-dose subcutaneous unfractionated or low molecular weight heparin for I year or more, baseline bone density studies arc recommended and repeat comparative stUdies should be done yearly. If a significant change OCCurs and continued heparin is required, alendronate should be started (57) .
HEPARIN-RELATED SKIN REACTIONS
Three general types of skin reactions can occur with heparin therapy (17, 18, 58) . The most common are those seen in patients being treated with subcutaneous heparin. These are small ecchymotic or erythematous papular or nodular lesions that are slightly tender and generally < I ern, These occur at the site of injection. Although at times these are the result of violated sterile technique and therefore, represent infections, most are sterile and require no change in therapy except selection of an alternate site. The exact mechanism is not certain, but local cytokine release is the current working concept.
A second skin reaction is that of urticarial, often pruritic, lesions; again largely at the site of subcutaneous injection. These allergic reactions have commonly been associated with the vehicle for the heparin and can often be avoided by a change in the brand of heparin or the use of an antihistamine at the time of injection.
Heparin-induced skin necrosis is the most serious form of dermal reaction and fortunately the least common (58) (59) (60) (61) (62) (63) . These lesions have many features similar to coumadin necrosis, but the pathophysiology is distinctly different. The route and form of heparin is unrelated to this occurrence. Commonly these begin 5 to 10 days into the heparin therapy and are manifest on the extremities, abdominal wall, or nose, and several case reports highlight their occurrence on the dorsum of the hand (61) (62) (63) . The onset is abrupt with a dusky or erythematous plaquelike lesion that can rapidly evolve into a hemorrhagic bullae with necrosis. The exact pathophysiologic basis for these necrotic lesions is not clear. The antibodies found in heparin-induced thrombocytopenia have been found in many of the patients in whom it has been sought, yet only about 25% of patients will actually develop HIT. These lesions signal an acute need to discontinue heparin therapy and select an appropriate alternative agent.
ALTERED LIVER FUNCTION TESTS
Abnormal liver function studies, primarily a transaminasemia of minimal degree, have been correlated with long-term heparin administration. The finding is uncommon and the pathophysiologic mechanisms have never been defined. These changes revert to normal when the heparin is discontinued.
HEPARIN AND EOSINOPHILIA
Eosinophilia occurs in 5% to 10% of patients receiving unfractionated or low molecular weight heparin therapy (17, 18, 64) . The eosinophilia is asymptomatic. In almost all patients it is unrelated to systemic allergic reactions, dermal allergic reactions, skin necrosis, or any other evident symptom complex. It is not associated with any physiologic changes or sequelae. The eosinophilia abates 4-8 weeks after cessation of heparin therapy. The current hypothesis relative to this occurrence is the activation of CD4 cells with the subsequent release of OM-CSF, IL-3, and IL-5, which can induce eosinophilia (65).
HYPERKALEMIA, HYPOALDOSTERONISM, AND RELATED METABOLIC ABNORMALITIES
Prolonged heparin therapy has been recognized to be associated with functional hypoaldosteronism, hyperkalemia, and correlated metabolic abnormalities (19, 66, 67) . Although rare, the evidence supports heparin suppression of synthesis of aldosterone (67) . Cessation of heparin results in resolution of metabolic abnormalities and return to normal.
PRIAPISM
Priapism has been considered to be a possible complication of heparin therapy (19) . In the few reports available, it is not clear whether specificity of a vascular occlusive event is present or whether this simply represents thrombosis as part of an HIT event. We favor this latter pathophysiologic explanation.
ALOPECIA
Alopecia has been related to long-term heparin therapy (17) (18) (19) . Neither its occurrence nor potential pathophysiologic mechanisms have been wel1 defined.
